Equillium Inc (NAS:EQ)
$ 1.54 0 (0%) Market Cap: 54.29 Mil Enterprise Value: 22.73 Mil PE Ratio: 0 PB Ratio: 2.58 GF Score: 34/100

Equillium Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript

Mar 30, 2023 / 05:30PM GMT
Release Date Price: $0.7233 (+2.02%)
Ram Selvaraju;Bruce Steel
H.C. Wainwright & Co. - Analyst;Equillium, Inc

Hello, everyone, and welcome to this next in our series of fireside chats as part of the H.C. Wainwright Conference, focusing on autoimmune and inflammatory skin conditions within the context of dermatology. My name is Ram Selvaraju. I'm a managing director and senior healthcare equity research analyst here at H.C. Wainwright. I'm joined here by Steve Connelly and Bruce Steel from the management team of Equillium.

Equillium is currently traded on the NASDAQ under the ticker symbol EQ. We cover Equillium with a buy rating. I think it would be helpful perhaps just to contextualize things for our audience.

Bruce, if you could describe Equillium's original genesis around the molecule known as itolizumab, the fact that the company has recently executed a transformative transaction to put that company into the hands of Ono. And also then we can proceed to discuss Equillium's focus with respect to its endogenous pipeline, on particular, dermatological condition, alopecia areata. Bruce?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot